Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Sep 28

PMID 37765153

Authors

Jingjing Zhang

Yuheng Liu

Chao Li

Qin Xiao

Dandan Zhang

Yang Chen

Joseph Rosenecker

Xiaoyan Ding

Shan Guan

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic poses a disruptive impact on public health and the global economy. Fortunately, the development of COVID-19 vaccines based on in vitro-transcribed messenger RNA (IVT mRNA) has been a breakthrough in medical history, benefiting billions of people with its high effectiveness, safety profile, and ease of large-scale production. This success is the result of decades of continuous RNA research, which has led to significant improvements in the stability and expression level of IVT mRNA through various approaches such as sequence optimization and improved preparation processes. IVT mRNA sequence optimization has been shown to have a positive effect on enhancing the mRNA expression level. The innovation of IVT mRNA purification technology is also indispensable, as the purity of IVT mRNA directly affects the success of downstream vaccine preparation processes and the potential for inducing unwanted side effects in therapeutic applications. Despite the progress made, challenges related to IVT mRNA sequence design and purification still require further attention to enhance the quality of IVT mRNA in the future. In this review, we discuss the latest innovative progress in IVT mRNA design and purification to further improve its clinical efficacy.

Citing Articles

Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy.

Laila U, An W, Xu Z Front Immunol. 2024; 15:1448489.

PMID: 39654897 PMC: 11625737. DOI: 10.3389/fimmu.2024.1448489.

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.

Parvin N, Mandal T, Joo S Pharmaceutics. 2024; 16(11).

PMID: 39598489 PMC: 11597542. DOI: 10.3390/pharmaceutics16111366.

Synergistic integration of mRNA-LNP with CAR-engineered immune cells: Pioneering progress in immunotherapy.

Chen Z, Shu J, Hu Y, Mei H Mol Ther. 2024; 32(11):3772-3792.

PMID: 39295145 PMC: 11573621. DOI: 10.1016/j.ymthe.2024.09.019.

A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice.

Liu J, Sun J, Ding X, Liu W, Wang Y, Wang Z Emerg Microbes Infect. 2024; 13(1):2389115.

PMID: 39129566 PMC: 11328811. DOI: 10.1080/22221751.2024.2389115.

Detection and Quantification of 5moU RNA Modification from Direct RNA Sequencing Data.

Li J, Sun F, He K, Zhang L, Meng J, Huang D Curr Genomics. 2024; 25(3):212-225.

PMID: 39086998 PMC: 11288159. DOI: 10.2174/0113892029288843240402042529.

References

Pereira M, Behera V, Walter N . Nondenaturing purification of co-transcriptionally folded RNA avoids common folding heterogeneity. PLoS One. 2010; 5(9):e12953. PMC: 2944885. DOI: 10.1371/journal.pone.0012953. View

Baronti L, Karlsson H, Marusic M, Petzold K . A guide to large-scale RNA sample preparation. Anal Bioanal Chem. 2018; 410(14):3239-3252. PMC: 5937877. DOI: 10.1007/s00216-018-0943-8. View

Henderson J, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N . Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap Analog by In Vitro Transcription. Curr Protoc. 2021; 1(2):e39. DOI: 10.1002/cpz1.39. View

Roest S, Hoek R, Manintveld O . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(20):1968-1970. DOI: 10.1056/NEJMc2104281. View

To K, Cho W . An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov. 2021; 16(11):1307-1317. DOI: 10.1080/17460441.2021.1935859. View

Azarani A, Hecker K . RNA analysis by ion-pair reversed-phase high performance liquid chromatography. Nucleic Acids Res. 2001; 29(2):E7. PMC: 29688. DOI: 10.1093/nar/29.2.e7. View

Yu S, Kim V . A tale of non-canonical tails: gene regulation by post-transcriptional RNA tailing. Nat Rev Mol Cell Biol. 2020; 21(9):542-556. DOI: 10.1038/s41580-020-0246-8. View

Weisman G, Camden J, Peterson T, Ajit D, Woods L, Erb L . P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y₂ receptor interactions in neuroinflammation. Mol Neurobiol. 2012; 46(1):96-113. PMC: 3439567. DOI: 10.1007/s12035-012-8263-z. View

Inagaki M, Abe N, Li Z, Nakashima Y, Acharyya S, Ogawa K . Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat Commun. 2023; 14(1):2657. PMC: 10175277. DOI: 10.1038/s41467-023-38244-8. View

10.

Urbina F, Morales-Pison S, Maldonado E . Enzymatic Protein Biopolymers as a Tool to Synthetize Eukaryotic Messenger Ribonucleic Acid (mRNA) with Uses in Vaccination, Immunotherapy and Nanotechnology. Polymers (Basel). 2020; 12(8). PMC: 7463467. DOI: 10.3390/polym12081633. View

11.

Kwon S, Kwon M, Im S, Lee K, Lee H . mRNA vaccines: the most recent clinical applications of synthetic mRNA. Arch Pharm Res. 2022; 45(4):245-262. PMC: 9012156. DOI: 10.1007/s12272-022-01381-7. View

12.

Kim I, McKenna S, Puglisi E, Puglisi J . Rapid purification of RNAs using fast performance liquid chromatography (FPLC). RNA. 2006; 13(2):289-94. PMC: 1781364. DOI: 10.1261/rna.342607. View

13.

Lima S, Chipman L, Nicholson A, Chen Y, Yee B, Yeo G . Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017; 24(12):1057-1063. PMC: 5877826. DOI: 10.1038/nsmb.3499. View

14.

Cannarozzi G, Cannarrozzi G, Schraudolph N, Faty M, von Rohr P, Friberg M . A role for codon order in translation dynamics. Cell. 2010; 141(2):355-67. DOI: 10.1016/j.cell.2010.02.036. View

15.

Spencer P, Siller E, Anderson J, Barral J . Silent substitutions predictably alter translation elongation rates and protein folding efficiencies. J Mol Biol. 2012; 422(3):328-35. PMC: 3576719. DOI: 10.1016/j.jmb.2012.06.010. View

16.

Kwon H, Kim M, Seo Y, Moon Y, Lee H, Lee K . Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials. 2017; 156:172-193. DOI: 10.1016/j.biomaterials.2017.11.034. View

17.

Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S . The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020; 40:107534. DOI: 10.1016/j.biotechadv.2020.107534. View

18.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

19.

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571. PMC: 7581537. DOI: 10.1038/s41586-020-2622-0. View

20.

Xia X . Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel). 2021; 9(7). PMC: 8310186. DOI: 10.3390/vaccines9070734. View